Oxler Private Wealth LLC trimmed its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 14.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,588 shares of the financial services provider’s stock after selling 272 shares during the period. Oxler Private Wealth LLC’s holdings in iShares Biotechnology ETF were worth $218,000 as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. Crewe Advisors LLC boosted its position in iShares Biotechnology ETF by 42.9% during the 4th quarter. Crewe Advisors LLC now owns 260 shares of the financial services provider’s stock worth $35,000 after acquiring an additional 78 shares during the last quarter. Apexium Financial LP boosted its stake in shares of iShares Biotechnology ETF by 3.8% during the 4th quarter. Apexium Financial LP now owns 2,223 shares of the financial services provider’s stock worth $302,000 after buying an additional 82 shares during the last quarter. Perkins Coie Trust Co grew its stake in iShares Biotechnology ETF by 0.3% in the second quarter. Perkins Coie Trust Co now owns 25,184 shares of the financial services provider’s stock valued at $3,457,000 after purchasing an additional 83 shares in the last quarter. Optimum Investment Advisors grew its stake in shares of iShares Biotechnology ETF by 2.9% in the second quarter. Optimum Investment Advisors now owns 3,024 shares of the financial services provider’s stock valued at $415,000 after buying an additional 85 shares in the last quarter. Finally, Penbrook Management LLC increased its holdings in iShares Biotechnology ETF by 2.3% during the first quarter. Penbrook Management LLC now owns 4,050 shares of the financial services provider’s stock worth $556,000 after buying an additional 90 shares during the last quarter. 62.45% of the stock is owned by institutional investors.
iShares Biotechnology ETF Stock Performance
NASDAQ IBB traded down $0.11 on Friday, hitting $148.17. 664,286 shares of the stock were exchanged, compared to its average volume of 1,544,753. The business’s fifty day moving average is $143.44 and its 200 day moving average is $137.63. iShares Biotechnology ETF has a 52 week low of $111.83 and a 52 week high of $150.17.
iShares Biotechnology ETF Company Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
See Also
- Five stocks we like better than iShares Biotechnology ETF
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- The Solar Stock Battle: Is Daqo or JinkoSolar Your Next Big Win?
- What is the Hang Seng index?
- Are These Chinese Stocks a Buy? Michael Burry’s Top Picks Say Yes
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Five Below Stock Faces Challenges Despite Strong Revenue Growth
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.